To date, BeiGene has announced positive readouts from 10 Phase 3 pivotal studies across multiple tumor types and disease settings such as NSCLC, Small Cell Lung Cancer, Gastric Cancer, ESCC ...

ESCC accounts for 80% of cases of esophageal ... including a study involving patients with extensive stage small cell lung cancer. However, phase 1a/1b results published in JAMA Oncology in ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

Yaoyao Zhu, MD, Department of Radiation Oncology, Shanghai Pulmonary Hospital, Shanghai, China, presented the new research at the IASLC World Conference on Lung Cancer (WCLC) 2024 on September 10.

Shortly after the FDA delayed a decision for Novartis and BeiGene’s tislelizumab in previously treated esophageal squamous cell carcinoma (ESCC), the ... non-small cell lung cancer (NSCLC).

The drug is already approved in the EU to treat certain cases of oesophageal squamous cell carcinoma (ESCC), gastric or gastroesophageal junction (G/GEJ) adenocarcinoma and non-small lung cancer. The ...

A reason for poor treatment outcomes is the high recurrence of ESCC, with only 55% to 63.6% of patients remaining cancer-free five years after treatment. Given the urgent need for effective ...

New findings in indicate that periostin, or POSTN, promotes ESCC progression by enhancing cancer and stromal cell migration in cancer-associated fibroblasts (CAFs). Therefore, it may be a novel ...

While immunotherapy has improved outcomes in advanced esophageal cancer, its superiority over ... This study included 1428 patients with locally advanced ESCC (median age, 63 years; 82.9% men).